Linked Data API

Show Search Form

Search Results

1734398
registered interest false more like this
date less than 2024-10-15more like thismore than 2024-10-15
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will hold discussions with the Lancashire Teaching Hospital Trust on the potential merits of enabling clinicians to prescribe unlicensed cannabis products to children for clinical reasons. more like this
tabling member constituency South Ribble more like this
tabling member printed
Mr Paul Foster more like this
uin 9250 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-10-21more like thismore than 2024-10-21
answer text <p>The National Institute for Health and Care Excellence (NICE) has published technology appraisals recommending Epidyolex, a licensed form of cannabidiol extracted from cannabis, for the treatment of seizures associated with two rare forms of epilepsies, specifically Dravet syndrome and Lennox-Gastaut syndrome, and tuberous sclerosis complex.</p><p>Deciding whether to prescribe an unlicensed cannabis-based medicine, a medicine that has not been assessed or approved by the medicines regulator, is a clinical decision, and the funding of medicines within the National Health Service is governed by well-established processes and evidence-based guidelines produced by the NICE. The NICE found that there is insufficient evidence of safety and effectiveness to support a population-wide recommendation in relation to unlicensed cannabis-based medicines for severe treatment-resistant epilepsy. The NICE also calls for further research.</p><p>Following the publication of the NICE’s guidance, NHS England and The National Institute for Health and Care Research (NIHR) has agreed funding for two trials relating to the use of cannabis-based medicines for the treatment of difficult-to-treat epilepsies. These will be world-first trials and will be crucial in informing future NHS funding decisions. Due to commercial confidentiality, further information on the trials cannot be released at this time.</p><p>Where a treatment is not currently routinely funded by the NHS in England, an NHS clinician can, on behalf of their patient, make an application for funding in exceptional clinical circumstances. This is known as an Individual Funding Request (IFR). In making an application for an IFR, clinicians must demonstrate that the patient in question is clinically exceptional compared to the wider group of patients with the same condition, and is likely to derive greater benefit from the treatment. Each case is assessed on an individual basis, and is not a process the Government can seek to influence.</p><p>Until the evidence base improves, prescribers will remain reticent in prescribing, and no decision can be made by the NHS on routine funding. That is why the Government is committed to research and catalysing the generation of evidence to support use of these products.</p><p>Like any other area of medicine, manufacturers of these products must invest in research and clinical trials to ensure that cannabis-based medicines are proven both safe and effective before they can be considered for routine funding by the NHS. The NIHR remains open to receiving good quality proposals for research in this area as a priority, and stands ready to support researchers and manufacturers to develop applications.</p>
answering member constituency Gorton and Denton more like this
answering member printed Andrew Gwynne more like this
grouped question UIN
9248 more like this
9249 more like this
9251 more like this
question first answered
less than 2024-10-21T10:44:09.807Zmore like thismore than 2024-10-21T10:44:09.807Z
answering member
1506
label Biography information for Andrew Gwynne more like this
tabling member 5074
1734399
registered interest false more like this
date less than 2024-10-15more like thismore than 2024-10-15
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will undertake a review of NHS policy on the assessment of individual funding requests to support children for whom prescribing medical cannabis could help prevent repeated admissions to hospital. more like this
tabling member constituency South Ribble more like this
tabling member printed
Mr Paul Foster more like this
uin 9251 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-10-21more like thismore than 2024-10-21
answer text <p>The National Institute for Health and Care Excellence (NICE) has published technology appraisals recommending Epidyolex, a licensed form of cannabidiol extracted from cannabis, for the treatment of seizures associated with two rare forms of epilepsies, specifically Dravet syndrome and Lennox-Gastaut syndrome, and tuberous sclerosis complex.</p><p>Deciding whether to prescribe an unlicensed cannabis-based medicine, a medicine that has not been assessed or approved by the medicines regulator, is a clinical decision, and the funding of medicines within the National Health Service is governed by well-established processes and evidence-based guidelines produced by the NICE. The NICE found that there is insufficient evidence of safety and effectiveness to support a population-wide recommendation in relation to unlicensed cannabis-based medicines for severe treatment-resistant epilepsy. The NICE also calls for further research.</p><p>Following the publication of the NICE’s guidance, NHS England and The National Institute for Health and Care Research (NIHR) has agreed funding for two trials relating to the use of cannabis-based medicines for the treatment of difficult-to-treat epilepsies. These will be world-first trials and will be crucial in informing future NHS funding decisions. Due to commercial confidentiality, further information on the trials cannot be released at this time.</p><p>Where a treatment is not currently routinely funded by the NHS in England, an NHS clinician can, on behalf of their patient, make an application for funding in exceptional clinical circumstances. This is known as an Individual Funding Request (IFR). In making an application for an IFR, clinicians must demonstrate that the patient in question is clinically exceptional compared to the wider group of patients with the same condition, and is likely to derive greater benefit from the treatment. Each case is assessed on an individual basis, and is not a process the Government can seek to influence.</p><p>Until the evidence base improves, prescribers will remain reticent in prescribing, and no decision can be made by the NHS on routine funding. That is why the Government is committed to research and catalysing the generation of evidence to support use of these products.</p><p>Like any other area of medicine, manufacturers of these products must invest in research and clinical trials to ensure that cannabis-based medicines are proven both safe and effective before they can be considered for routine funding by the NHS. The NIHR remains open to receiving good quality proposals for research in this area as a priority, and stands ready to support researchers and manufacturers to develop applications.</p>
answering member constituency Gorton and Denton more like this
answering member printed Andrew Gwynne more like this
grouped question UIN
9248 more like this
9249 more like this
9250 more like this
question first answered
less than 2024-10-21T10:44:09.84Zmore like thismore than 2024-10-21T10:44:09.84Z
answering member
1506
label Biography information for Andrew Gwynne more like this
tabling member 5074
1732907
registered interest false more like this
date less than 2024-10-09more like thismore than 2024-10-09
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many patients under the age of 18 are in receipt of an NHS funded cannabis-based (a) prescription and (b) medication. more like this
tabling member constituency South Ribble more like this
tabling member printed
Mr Paul Foster more like this
uin 8273 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-10-14more like thismore than 2024-10-14
answer text <p>The NHS Business Services Authority does not hold the information in the form requested as it is only a legal requirement for prescriptions to state the age for children under 12 years.</p><p>Between November 2018 and July 2024, 21,299 items of licensed cannabis-based medicines, namely Nabilone, Sativex and Epidyolex, were dispensed in the community in England against a National Health Service prescription.</p><p>Data on unlicensed cannabis-based medicines is withheld in accordance with the General Data Protection Regulation, due to the number of items attributed to fewer than five patients and enhanced risk of release of patient identifiable information.</p> more like this
answering member constituency Gorton and Denton more like this
answering member printed Andrew Gwynne more like this
question first answered
less than 2024-10-14T15:33:44.94Zmore like thismore than 2024-10-14T15:33:44.94Z
answering member
1506
label Biography information for Andrew Gwynne more like this
tabling member 5074
1689862
registered interest false more like this
date less than 2024-02-19more like thismore than 2024-02-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many people aged under 18 have been prescribed medicinal cannabis as of 19 February 2024. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon more like this
uin 14583 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-02-27more like thismore than 2024-02-27
answer text <p>The Department does not hold details relating to the age of people prescribed medicinal cannabis.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-27T11:18:22.867Zmore like thismore than 2024-02-27T11:18:22.867Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1689392
registered interest false more like this
date less than 2024-02-16more like thismore than 2024-02-16
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what plans her Department has to make medicinal cannabis more accessible to those who need it. more like this
tabling member constituency Liverpool, Wavertree more like this
tabling member printed
Paula Barker more like this
uin 14291 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-02-21more like thismore than 2024-02-21
answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence (NICE) demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p> </p><p>The Government continues to call on manufacturers to invest in research and clinical trials to prove if their products are safe and effective and offers scientific and research advice from the Medicines and Healthcare products Regulatory Agency and the NICE.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-21T09:43:53.517Zmore like thismore than 2024-02-21T09:43:53.517Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4828
label Biography information for Paula Barker more like this
1687065
registered interest false more like this
date less than 2024-02-02more like thismore than 2024-02-02
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what progress she has made with (a) regulatory, (b) research and (c) NHS partners on establishing clinical trials to test the (i) safety and (ii) efficacy of medical cannabis products. more like this
tabling member constituency Somerton and Frome more like this
tabling member printed
Sarah Dyke more like this
uin 12872 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-02-09more like thismore than 2024-02-09
answer text <p>The Department, via the National Institute for Health and Care Research (NIHR), is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and the results will be published once the trials have completed and the findings peer reviewed.</p><p> </p><p>Furthermore, the Government continues to encourage manufacturers to invest in research and has highlighted that public funding is available for high quality applications. The Medicines and Healthcare products Regulatory Agency and the NIHR can provide applicants with scientific and research advice.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-09T10:47:53.36Zmore like thismore than 2024-02-09T10:47:53.36Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4995
label Biography information for Sarah Dyke more like this
1682606
registered interest false more like this
date less than 2024-01-16more like thismore than 2024-01-16
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the potential merits of allowing children to be issued medical cannabis prescriptions on the NHS. more like this
tabling member constituency Somerton and Frome more like this
tabling member printed
Sarah Dyke more like this
uin 9974 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-01-22more like thismore than 2024-01-22
answer text <p>Licensed cannabis-based medicines, that have been proved effective in clinical trials and judged cost-effective by the National Institute of Health and Care Excellence (NICE), are routinely available on the National Health Service, including for people aged over two years old with certain types of epilepsy. However, clinical guidelines from NICE demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-01-22T14:04:14.56Zmore like thismore than 2024-01-22T14:04:14.56Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4995
label Biography information for Sarah Dyke more like this
1681903
registered interest false more like this
date less than 2024-01-15more like thismore than 2024-01-15
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make an assessment of the effectiveness of medicinal cannabis treatments provided by the NHS; and whether she has plans to increase the number of treatments available. more like this
tabling member constituency Romford more like this
tabling member printed
Andrew Rosindell more like this
uin 9453 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2024-01-17more like thismore than 2024-01-17
answer text <p>Licensed cannabis-based medicines are available and funded on the National Health Service, where the safety, quality and clinical and cost effectiveness has been assessed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence.</p><p>The Government continues to encourage manufacturers to develop new treatments and invest in research and clinical trials, and offers scientific and research advice from the MHRA and the National Institute for Health and Care Research.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-01-17T17:12:08.693Zmore like thismore than 2024-01-17T17:12:08.693Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
1447
label Biography information for Andrew Rosindell more like this
1663633
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether the Government is taking steps to reduce inequalities in access to medicinal cannabis prescribed under the NHS. more like this
tabling member constituency York Outer more like this
tabling member printed
Julian Sturdy more like this
uin 201487 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local National Health Service decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality, and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-19T14:43:27.227Zmore like thismore than 2023-10-19T14:43:27.227Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4079
label Biography information for Julian Sturdy more like this
1663778
registered interest false more like this
date less than 2023-10-13more like thismore than 2023-10-13
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care remove filter
hansard heading Cannabis: Medical Treatments remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will take steps to increase access to cannabis-based medicinal products on the NHS. more like this
tabling member constituency Ealing Central and Acton more like this
tabling member printed
Dr Rupa Huq more like this
uin 201631 more like this
answer
answer
is ministerial correction false remove filter
date of answer less than 2023-10-19more like thismore than 2023-10-19
answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local NHS decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> more like this
answering member constituency Colchester more like this
answering member printed Will Quince more like this
question first answered
less than 2023-10-19T11:14:45.24Zmore like thismore than 2023-10-19T11:14:45.24Z
answering member
4423
label Biography information for Will Quince more like this
tabling member
4511
label Biography information for Dr Rupa Huq more like this